PRF Technologies (PRFX) Liabilities and Shareholders Equity (2019 - 2025)
PRF Technologies (PRFX) recorded quarterly Liabilities and Shareholders Equity of $12.0 million in Q4 2025, up 7.49% on a QoQ basis from $11.2 million in Q2 2025, and up 165.15% year-over-year from $4.5 million in Q4 2024.
PRF Technologies (PRFX) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends
PRF Technologies has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $12.0 million for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 165.15% year-over-year to $12.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.8 million (up 129.96% YoY) and the FY2025 annual result came in at $12.0 million, up 165.15% from the prior year.
- Liabilities and Shareholders Equity climbed to $12.0 million in Q4 2025, from $11.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $21.4 million in Q1 2021 and troughed at $389000.0 in Q4 2023.
- A 5-year average of $12.2 million and a median of $12.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 2267.3% — and 2023, when it slumped 96.84%.
- Tracing PRFX's Liabilities and Shareholders Equity over 5 years: stood at $19.1 million in 2021, then tumbled by 35.36% to $12.3 million in 2022, then sank by 96.84% to $389000.0 in 2023, then surged by 1063.24% to $4.5 million in 2024, then jumped by 165.15% to $12.0 million in 2025.
- Business Quant data shows PRFX's Liabilities and Shareholders Equity at $12.0 million in Q4 2025, $11.2 million in Q2 2025, and $4.5 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | PRF Technologies | 933,081.16 | -2.46 Mn | - | 12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.00 Mn |
| Jun 30, 2025 | 11.16 Mn |
| Dec 31, 2024 | 4.53 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 5.37 Mn |
| Dec 31, 2023 | 389,000.00 |
| Sep 30, 2023 | 10.89 Mn |
| Jun 30, 2023 | 8.32 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Dec 31, 2022 | 12.33 Mn |
| Sep 30, 2022 | 14.85 Mn |
| Jun 30, 2022 | 15.99 Mn |
| Mar 31, 2022 | 17.71 Mn |
| Dec 31, 2021 | 19.07 Mn |
| Sep 30, 2021 | 20.34 Mn |
| Jun 30, 2021 | 19.84 Mn |
| Mar 31, 2021 | 21.35 Mn |
| Dec 31, 2020 | 17.80 Mn |
| Jun 30, 2020 | 838,000.00 |
| Dec 31, 2019 | 1.16 Mn |